Align Technology (NASDAQ:ALGN) Issues Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Align Technology (NASDAQ:ALGN - Get Free Report) released its earnings results on Wednesday. The medical equipment provider reported $2.13 EPS for the quarter, beating the consensus estimate of $2.00 by $0.13, Briefing.com reports. The firm had revenue of $979.26 million for the quarter, compared to analysts' expectations of $977.90 million. Align Technology had a net margin of 10.54% and a return on equity of 13.84%. Align Technology's quarterly revenue was down 1.8% on a year-over-year basis. During the same quarter last year, the company earned $2.14 EPS. Align Technology updated its Q2 2025 guidance to EPS.

Align Technology Price Performance

ALGN traded down $2.21 during midday trading on Monday, hitting $177.61. 920,473 shares of the company's stock traded hands, compared to its average volume of 906,347. The company has a market cap of $13.00 billion, a PE ratio of 31.66, a price-to-earnings-growth ratio of 2.24 and a beta of 1.68. Align Technology has a one year low of $141.74 and a one year high of $291.80. The stock's fifty day simple moving average is $168.42 and its 200-day simple moving average is $200.91.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ALGN shares. HSBC cut Align Technology from a "buy" rating to a "hold" rating and lowered their price target for the company from $290.00 to $170.00 in a research report on Friday, April 25th. Leerink Partners upgraded shares of Align Technology from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $235.00 to $280.00 in a research report on Monday, January 6th. Jefferies Financial Group dropped their price target on Align Technology from $285.00 to $260.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Piper Sandler reaffirmed an "overweight" rating and set a $250.00 target price (up from $235.00) on shares of Align Technology in a research report on Thursday. Finally, Morgan Stanley decreased their price objective on shares of Align Technology from $280.00 to $272.00 and set an "overweight" rating for the company in a research note on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $241.25.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.